Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (14059)	9/26/1998 2:40:00 PM
From: BDR	Read Replies (1) \| Respond to of 18691

Re: SCTR/XMIT Datek had indicated that this was not marginable/shortable right after the name and symbol change. Just browsing around Datek today and noted that the restriction seems to have been lifted. Shorted XMIT (then SCTR) on 8/20 at 29 3/8 (and wanting ever since to add to my position as I watched it fall).

To: BDR who wrote (14059)	9/30/1998 2:14:00 AM
From: BDR	Read Replies (3) \| Respond to of 18691

HEPH- website (http://www.holliseden.com/) is operational (wear hip boots) "The cellular energy regulator HE2000 is Hollis-Eden's patented analogue of a human molecule that has been shown to inhibit energy-producing enzymes and other cellular proteins that are necessary for retroviral replication. The company recently completed pre-clinical testing for HE2000. When tested in vitro against strains of HIV that had developed resistance to all current combination therapies, HE2000 showed significant inhibition of viral replication and a ten-fold increase in potency over the company's native drug candidate that was previously tested in human clinical trials. This clinical plan is supported by both in vitro and in vivo studies. In one clinical study conducted with the company's native drug candidate for cellular energy regulation, multiple HIV/AIDS patients were treated at Twelve Oaks Hospital in Houston, Texas. Preliminary findings revealed no observable toxicity and no adverse side effects. In addition, the trial in Houston demonstrated that, when the company's native drug candidate was used as a monotherapy, clinically and statistically significant reductions in viral load were seen in HIV-infected patients with CD-4 counts between 50 and 300 cells/mm3. In the United States, Hollis-Eden Pharmaceuticals intends to file an IND for HE2000 to initiate Phase I / II clinical trials in the fourth quarter." A search of the IBM Patent Search site patents.ibm.com yielded only this: patents.ibm.com In February, 1997, Inactivin was DHEA. In February, 1998, Inactivin became PPB2. PPB2 is now, I believe HE2000. Gotta keep up with these guys. The Houston trial referred to at the website using the "company's native drug cabdidate" utilized DHEA. Reminder: DHEA is a generic, non-patentable, "nutritional supplement". I don't believe that any of the results of the many trials referred to at the website have been published in peer reviewed journals. References are sorely lacking at the website. I am short HEPH.